Oral Abstracts

Sonalkar, Sarita; Fishman, Jessica; Kete, Corinne; McAllister, A. Kimberley; Frarey, Alhambra; Wr, Short; Schreiber, C.A.; Teitelman, Anne M.

doi:10.1016/j.contraception.2021.07.011

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondarily, the presence of a foreign device causes an inflammatory response, which has a spermicidal effect. It is important to underline how ovulation is not inhibited by the presence of copper IUDs [ 25 , 26 , 27 , 28 ]. Therefore, this treatment is not effective for some important pathologies in women, such as endometriosis, dysmenorrhea, menorrhagia, or PCOs; the latter in fact are very common reasons for women to use hormonal-based treatments [ 29 ].…”

Section: Possible Therapeutic Strategies For Adpkd Patientsmentioning

confidence: 99%

“…These devices act mostly by thickening the cervical mucus and changing the pattern of the endometrium [ 28 , 29 , 30 , 31 ]. Sometimes they can also suppress ovulation, but most women continue to ovulate with LNG-IUD, especially the low-dose one [ 28 ]. Patients often become amenorrheic while the LNG-IUD is in place.…”

Section: Possible Therapeutic Strategies For Adpkd Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Role of Female Sex Hormones in ADPKD Progression and a Personalized Approach to Contraception and Hormonal Therapy

Petrone,

Catania,

De Rosa

et al. 2024

JCM

View full text Add to dashboard Cite

This review navigates the intricate relationship between gender, hormonal influences, and the progression of autosomal dominant polycystic kidney disease (ADPKD), highlighting the limited literature on this crucial topic. The study explores the impact of female sex hormones on liver and renal manifestations, uncovering gender-specific differences in disease progression. Actually, hormonal therapy in women with ADPKD remains a challenging issue and is a source of concern regarding its potential impact on disease outcomes, particularly at the hepatic level. Notably, women with ADPKD exhibit a slower renal disease progression compared to men, attributed to hormonal dynamics. This review sheds light on the role of estrogen in regulating pathways of the renin–angiotensin–aldosterone system, revealing its complex interplay and implications for cardiovascular and renal health. Therapeutic considerations for fertile women with ADPKD, including contraception options, are discussed, emphasizing the necessity for personalized approaches. In the postmenopausal phase, the review evaluates the role of hormonal replacement therapy, considering its potential benefits and risks in the context of ADPKD. The review concludes by underscoring the imperative need for tailored treatment approaches for ADPKD patients, considering individual risks and benefits. The scarcity of literature underlines the call for further research to enhance our understanding of optimal hormonal therapies in the context of ADPKD, ultimately paving the way for innovative and personalized therapeutic interventions.

show abstract